UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 04/2007, Volume 356, Issue 15, pp. 1527 - 1535
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Biological and medical sciences | General aspects | Medical sciences | Tumors of the nervous system. Phacomatoses | Radiotherapy Dosage | Astrocytoma - radiotherapy | Astrocytoma - therapy | Humans | Proportional Hazards Models | Male | Glioblastoma - radiotherapy | Glioblastoma - therapy | Brain Neoplasms - therapy | Survival Analysis | Aged, 80 and over | Quality of Life | Female | Aged | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Glioblastoma - mortality | Astrocytoma - mortality | Cognition - radiation effects | Aged patients | Usage | Drug therapy | Radiotherapy | Glioblastoma multiforme | Survival analysis | Radiation therapy | Brain cancer | Older people | Standards | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 12/2015, Volume 125, Issue 3, pp. 551 - 583
Neurology | Radiation sensitizer | Practice guideline | Medicine & Public Health | Radiation | Oncology | Systematic review | Low grade glioma | Astrocytoma | Oligodendroglioma | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neoplasm Grading | Glioma - pathology | Humans | Brain Neoplasms - pathology | Disease Management | Brain Neoplasms - radiotherapy | Evidence-Based Medicine | Glioma - radiotherapy | Practice guidelines (Medicine) | Care and treatment | Radiotherapy | Gliomas | Evidence-based medicine | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 582 - 587
antiangiogenic therapy | glioblastoma | high‐grade glioma | signal transduction inhibitors | cabozantinib | high-grade glioma | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Astrocytoma - therapy | Nausea - chemically induced | Humans | Middle Aged | Brain Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Fatigue - chemically induced | Neurosurgical Procedures | Astrocytoma - pathology | Neoplasm Grading | Maintenance Chemotherapy - methods | Hypertension - chemically induced | Dacarbazine - analogs & derivatives | Adult | Female | Neutropenia | Chemoradiotherapy - methods | Dacarbazine - administration & dosage | Pyridines - administration & dosage | Leukopenia | Diarrhea | Treatment Outcome | Thrombocytopenia - chemically induced | Chemoradiotherapy, Adjuvant - methods | Constipation - chemically induced | Glioblastoma - therapy | Maximum Tolerated Dose | Anilides - administration & dosage | Aspartate Aminotransferases - blood | L-Lactate Dehydrogenase - blood | Glioblastoma - pathology | Brain Neoplasms - therapy | Aged | Usage | Care and treatment | Gliomas | Dosage and administration | Temozolomide | Diagnosis | Radiotherapy | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 707 - 715
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Astrocytoma - radiotherapy | Promoter Regions, Genetic | Dacarbazine - therapeutic use | Humans | DNA Repair Enzymes - genetics | Isocitrate Dehydrogenase - genetics | Male | Brain Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | DNA Methylation | DNA Modification Methylases - genetics | Tumor Suppressor Proteins - genetics | Astrocytoma - drug therapy | Dacarbazine - analogs & derivatives | Aged, 80 and over | Female | Aged | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Astrocytoma - mortality | Care and treatment | Oncology, Experimental | Radiation | Aged patients | Research | Antineoplastic agents | Radiotherapy | Biometry | Antimitotic agents | Chemotherapy | Nuclear radiation | Gliomas | Product development | Temozolomide | Cancer | Tumors | Index Medicus
Journal Article
Cancer biology & therapy, ISSN 1538-4047, 05/2014, Volume 15, Issue 5, pp. 504 - 509
radiotherapy | glioblastoma multiforme | high grade glioma | nimotuzumab | monoclonal antibody | anaplastic astrocytoma | Monoclonal antibody | Radiotherapy | Glioblastoma multiforme | Anaplastic astrocytoma | Nimotuzumab | High grade glioma | Life Sciences & Biomedicine | Oncology | Science & Technology | Astrocytoma - radiotherapy | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Brain Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Brain Neoplasms - drug therapy | Glioblastoma - radiotherapy | Young Adult | Disease-Free Survival | Astrocytoma - pathology | Neoplasm Grading | Glioblastoma - pathology | Astrocytoma - drug therapy | Adult | Female | Aged | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Index Medicus | Clinical Study
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2005, Volume 366, Issue 9490, pp. 985 - 990
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Biological and medical sciences | General aspects | Medical sciences | Tumors of the nervous system. Phacomatoses | Radiotherapy Dosage | Astrocytoma - radiotherapy | Oligodendroglioma - mortality | Humans | Middle Aged | Male | Survival Rate | Oligodendroglioma - radiotherapy | Disease Progression | Central Nervous System Neoplasms - radiotherapy | Disease-Free Survival | Adolescent | Adult | Female | Aged | Astrocytoma - mortality | Central Nervous System Neoplasms - mortality | Evaluation | Care and treatment | Radiotherapy | Gliomas | Usage | Diagnosis | Astrocytoma | Therapy | Adults | Long term health care | Brain cancer | Clinical outcomes | Radiation | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 8/2013, Volume 189, Issue 8, pp. 647 - 655
Progressionsfreies Überleben | Dosis-Wirkungs-Beziehung | Oncology | Radiotherapy | Dose–response relationship | Medicine & Public Health | Glioma | Gliom | Brachytherapy | Pädiatrie | Brachytherapie | Pediatric | Progression-free survival | Dose-response relationship | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Astrocytoma - radiotherapy | Prevalence | Prospective Studies | Astrocytoma - epidemiology | Humans | Male | Treatment Outcome | Germany - epidemiology | Young Adult | Disease-Free Survival | Brachytherapy - statistics & numerical data | Adolescent | Female | Brain Neoplasms - radiotherapy | Child | Brain Neoplasms - epidemiology | Pediatrics | Chemotherapy | Radioisotope brachytherapy | Gliomas | Analysis | Development and progression | Cancer | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 09/2017, Volume 8, Issue 40, pp. 69038 - 69046
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 01/2015, Volume 62, Issue 1, pp. 35 - 39
radiation | low‐grade glioma | pediatrics | pseudoprogression juvenile pilocytic astrocytoma | Pediatrics | Pseudoprogression juvenile pilocytic astrocytoma | Low-grade glioma | Radiation | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Brain Neoplasms - pathology | Radiation Injuries - diagnosis | Child, Preschool | Male | Survival Rate | Radiotherapy - adverse effects | Glioma - radiotherapy | Disease Progression | Radiation Injuries - etiology | Diagnostic Imaging | Neoplasm Grading | Glioma - pathology | Adolescent | Female | Brain Neoplasms - radiotherapy | Child | Radiotherapy | Gliomas | Development and progression | Index Medicus
Journal Article